FDA Fast Tracks Potential RP Treatment
Aldeyra’s ADX-2191 has received Fast Track Designation from the FDA for retinitis pigmentosa. With no approved treatments currently available for most RP patients, this milestone could help speed the development of a promising new therapy.

Hope for RP and Stargardt Disease
Nanoscope Therapeutics is advancing a one-time gene therapy designed to restore vision for patients with retinitis pigmentosa and Stargardt disease. If successful, this treatment could transform care for two conditions that currently have no approved therapies.

Stem Cell–Derived Retinal Sheets Trial for RP
A new clinical trial is testing DSP-3077, a one-time stem cell–derived retinal sheet implant, as a potential treatment for retinitis pigmentosa. This regenerative therapy could offer hope for patients regardless of genetic subtype. Learn how this groundbreaking study may shape the future of RP treatment.

A groundbreaking Phase 2 trial has shown the first-ever vision improvements in people with Stargardt disease — a condition with no approved treatment. Nanoscope Therapeutics’ gene-agnostic MCO-010 therapy produced meaningful gains in vision without serious side effects, paving the way for a pivotal Phase 3 trial starting in 2025.